---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-041317"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2023-12-12T23:59:59+00:00"
generated_at: "2026-06-07T14:16:27.066824+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics announces positive Phase 1 data for CFT7455 in relapsed/refractory multiple myeloma

## Summary
- Monotherapy dose escalation complete; 22 patients, median 7 prior therapies; 1 PR at 75 µg daily in BCMA-refractory patient.
- Combination with dexamethasone: 9 patients; 1 sCR and 1 PR at 37.5 µg daily, both BCMA refractory.
- CFT7455 well tolerated; no DLTs leading to discontinuation; common Grade 3+ AE: neutropenia (n=11).
- Optimal dosing schedule 14 days on/14 days off; immunomodulatory CD8+ T-cell activation observed.
- Dose escalation continues for combination and NHL; full Phase 1 data expected in 2024.

## SEC filing metadata
- accession: 0001628280-23-041317
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2023-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828023041317/0001628280-23-041317-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828023041317/cccc-20231212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-041317
- JSON: https://secwatch.observer/filing/0001628280-23-041317.json
- Plain text: https://secwatch.observer/filing/0001628280-23-041317.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.